Your browser doesn't support javascript.
Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study.
Fang, Jie; Li, Hui; Du, Wei; Yu, Ping; Guan, Ying-Yun; Ma, Shi-Yu; Liu, Dong; Chen, Wei; Shi, Guo-Chao; Bian, Xiao-Lan.
  • Fang J; Department of Pharmacy, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
  • Li H; Department of Pharmacy, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
  • Du W; Department of Respiration and Critical Care Disease, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
  • Yu P; School of Medicine, Institute of Respiratory Diseases, Shanghai Jiaotong University, Shanghai, China.
  • Guan YY; Department of Pharmacy, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
  • Ma SY; Department of Pharmacy, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
  • Liu D; Department of Pharmacy, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
  • Chen W; Department of Respiration and Critical Care Disease, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
  • Shi GC; School of Medicine, Institute of Respiratory Diseases, Shanghai Jiaotong University, Shanghai, China.
  • Bian XL; Department of Respiration and Critical Care Disease, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Front Pharmacol ; 11: 560209, 2020.
Article in English | MEDLINE | ID: covidwho-843841
Semantic information from SemMedBD (by NLM)
1. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
2. Pharmaceutical Preparations TREATS COVID-19
Subject
Pharmaceutical Preparations
Predicate
TREATS
Object
COVID-19
3. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
4. Pharmaceutical Preparations TREATS COVID-19
Subject
Pharmaceutical Preparations
Predicate
TREATS
Object
COVID-19
ABSTRACT

OBJECTIVE:

Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan City, China, coronavirus disease 2019 (COVID-19) has become a global pandemic. However, no special therapeutic drugs have been identified for COVID-19. The aim of this study was to search for drugs to effectively treat COVID-19. MATERIALS AND

METHODS:

We conducted a retrospective cohort study with a total of 162 adult inpatients (≥18 years old) from Ruijin Hospital (Shanghai, China) and Tongji Hospital (Wuhan, China) between January 27, 2020, and March 10, 2020. The enrolled COVID-19 patients were first divided into the Lianhuaqingwen (LHQW) monotherapy group and the LHQW + Arbidol combination therapy group. Then, these two groups were further classified into moderate and severe groups according to the clinical classification of COVID-19.

RESULTS:

The early combined usage of LHQW and Arbidol can significantly accelerate the recovery of patients with moderate COVID-19 by reducing the time to conversion to nucleic acid negativity, the time to chest CT improvement, and the length of hospital stay. However, no benefit was observed in severe COVID-19 patients treated with the combination of LHQW + Arbidol. In this study, both Arbidol and LHQW were well tolerated without serious drug-associated adverse events.

CONCLUSION:

The early combined usage of LHQW and Arbidol may accelerate recovery and improve the prognosis of patients with moderate COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Etiology study / Observational study / Randomized controlled trials / Risk factors Language: English Journal: Front Pharmacol Year: 2020 Document Type: Article Affiliation country: Fphar.2020.560209

Full text: Available Collection: International databases Database: MEDLINE Type of study: Etiology study / Observational study / Randomized controlled trials / Risk factors Language: English Journal: Front Pharmacol Year: 2020 Document Type: Article Affiliation country: Fphar.2020.560209